Janssen Pharma, a Johnson & Johnson subsidiary, has ended its anti-inflammation collaboration with Hutchison MediPharma, the drug R&D arm of Hutchison China MediTech. HMP will continue to develop the collaboration's lead molecule, HMP-507, a small molecule candidate that targets a novel inflammation/immunology kinase. To date, HMP has received $13 million in upfront, milestone and development payments for the program. No reason was given for Janssen's decision.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
